King's College London

A new FDA randomized controlled trial found that 5% of healthy adults developed elevated liver enzymes after taking low-dose CBD (5 mg/kg body weight) for four weeks, with women appearing more vulnerable than men.

University of Cambridge researchers used GPT-4 to identify drug combinations that could treat cancer, finding that three of 12 AI-suggested combinations outperformed current breast cancer drugs in laboratory tests.

Researchers from King's College London and Jagannath University discovered that gold-based cisplatin mimics contain a mixture of potentially dangerous isomers rather than a pure compound as previously believed for over 60 years.

A new clinical trial published in Lancet Psychiatry demonstrates that mindfulness-based cognitive therapy (MBCT) significantly improves symptoms in patients with difficult-to-treat depression compared to standard care.

A phase III clinical trial reveals that ubrogepant, an approved migraine medication, can effectively alleviate debilitating prodromal symptoms like fatigue, light sensitivity, and concentration difficulties that precede migraine headaches.

A groundbreaking UK trial has developed a highly sensitive bone marrow test that can detect returning Acute Myeloid Leukemia up to three months earlier than standard blood tests, potentially doubling survival rates for some patients.

A landmark Phase 3 clinical trial led by VCU and King's College London researchers found semaglutide significantly reduces liver inflammation and scarring in patients with metabolic dysfunction-associated steatohepatitis (MASH).

The Lupus Research Alliance has launched its Targeted Research Program on Engineered Cell Therapies for Lupus (TRP-ECT), awarding grants to 11 researchers developing innovative cellular treatments.

The NHS has approved a £10.7 million clinical trial to investigate the potential benefits of puberty blockers for young people with gender dysphoria, following recommendations from Baroness Cass's comprehensive review.

A meta-analysis of 23 publications involving 2,198 patients demonstrated that JAK inhibitors significantly reduce thromboembolic events by 48% in myeloproliferative neoplasm patients, with ruxolitinib showing a 59% reduction in polycythemia vera and myelofibrosis.